医学
贝尔麻痹
面瘫
听觉亢进
儿科
面神经
麻痹
病因学
麻痹
人口
听力损失
外科
听力学
内科学
病理
替代医学
环境卫生
作者
Jayaraman Rajangam,Arun Prasath Lakshmanan,K. Umamaheswara Rao,D Jayashree,Rajan Radhakrishnan,B. Roshitha,Palanisamy Senthilnathan,Manchikatla Sravani,K.Hanna Pravalika
出处
期刊:Cns & Neurological Disorders-drug Targets
[Bentham Science]
日期:2024-02-01
卷期号:23 (2): 203-214
被引量:1
标识
DOI:10.2174/1871527322666230321120618
摘要
Abstract: Bell palsy is a non-progressive neurological condition characterized by the acute onset of ipsilateral seventh cranial nerve paralysis. People who suffer from this type of facial paralysis develop a droop on one side of their face, or sometimes both. This condition is distinguished by a sudden onset of facial paralysis accompanied by clinical features such as mild fever, postauricular pain, dysgeusia, hyperacusis, facial changes, and drooling or dry eyes. Epidemiological evidence suggests that 15 to 23 people per 100,000 are affected each year, with a recurrence rate of 12%. It could be caused by ischaemic compression of the seventh cranial nerve, which could be caused by viral inflammation. Pregnant women, people with diabetes, and people with respiratory infections are more likely to have facial paralysis than the general population. Immune, viral, and ischemic pathways are all thought to play a role in the development of Bell paralysis, but the exact cause is unknown. However, there is evidence that Bell's hereditary proclivity to cause paralysis is a public health issue that has a greater impact on patients and their families. Delay or untreated Bell paralysis may contribute to an increased risk of facial impairment, as well as a negative impact on the patient's quality of life. For management, antiviral agents such as acyclovir and valacyclovir, and steroid treatment are recommended. Thus, early diagnosis accompanied by treatment of the uncertain etiology of the disorder is crucial. This paper reviews mechanistic approaches, and emerging medical perspectives on recent developments that encounter Bell palsy disorder.
科研通智能强力驱动
Strongly Powered by AbleSci AI